Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.